Omics analysis of HIV during synthetic opioid exposure

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2019
    2021
  • Known Financial Commitments (USD)

    $150,215
  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

    Pending
  • Research Location

    United States of America, Americas
  • Lead Research Institution

    UNIVERSITY OF CINCINNATI
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Drug users

  • Occupations of Interest

    Unspecified

Abstract

Abstract In December 2019, an outbreak of pneumonia of unknown cause occurred in Wuhan, China, and thecausative agent was identified as a novel coronavirus named severe acute respiratory syndrome coronavirus2 (SARS-CoV-2). Additionally, the US is in the midst of a major opioid epidemic largely attributed to synthetic opioids such as fentanyl, and the SARS-CoV-2 pandemic is occurring in parts of the world where recent increases in HIV due to the opioid crisis have been reported. With the SARS-CoV-2 pandemic, there are major concerns about worsening of the opioid crisis. People suffering from addiction are particularly vulnerable to increased infection with SARS-CoV-2 and more advanced disease severity. Many opioids are also associated with immune suppression and enhanced viral pathogenesis. Thus, foundational research on virus-virus and virus-opioid interactions is essential for understanding the impact of SARS-CoV-2 on other co-morbid conditions and for developing robust therapeutic options for limiting viral infection and pathogenesis in high-risk populations.